Clinical trials: Multiple Dose
HIV Infections
Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults
Antibodies are natural proteins that the body makes to fight infections. Antibodies can also be manufactured like a drug and infused or injected into the body to prevent or treat a disease.
- Trial name
- NCT02165267
- Testing
- VRC01
- Where
- 6 sites in United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy
A Study To Observe Safety And Blood Concentrations Of PF-04995274 During And Following the Administration of Multiple Doses Of PF-04995274 In Healthy Adult And Healthy Elderly Volunteers.
This study is designed to observe the safety and blood concentrations of PF-04995274 during and following the administration of multiple doses of PF-04995274 for a duration of 14 days, in healthy adult and healthy elderly.
- Trial name
- NCT01169714
- Testing
- 0.1 mg PF-04995274, 1 mg PF-04995274, 10 mg PF-04995274
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Pfizer
Filariasis
Safety, Tolerability and PK of Multiple-ascending Doses of Emodepside
The study evaluates safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of emodepside, after administration as a Liquid Service Formulation (LSF), over 10 days, in healthy male caucasian subjects.
- Trial name
- NCT03383614
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
Healthy Volunteers
IPI-145 Single Ascending, Multiple Ascending, Food Effect and Drug-Drug-Interaction Study
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of IPI-145 after single and repeat oral administration, and to evaluate the effects of food and ketoconazole on the plasma…
- Trial name
- NCT01549106
- Testing
- IPI-145
- Where
- Netherlands
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- SecuraBio
Drug Drug Interaction (DDI)
A Open-label, Drug-Drug Interaction With SB_MDZ in Healty Adult Subjects
This clinical trial is a phase 1, open-label, fixed-sequence, drug-drug interaction study to investigate the effect of single and multiple oral doses of SB17170 on the pharmacokinetics of SB_MDZ in healthy adult subjects.
- Trial name
- NCT06846684
- Testing
- SB17170, SB_MDZ
- Where
- South Korea
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- SPARK Biopharma
Healthy Adult Participants
A SINGLE CENTER, 5-PART STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF GAL-101 SALT IN HEALTHY ADULT AND ELDERLY PARTICIPANTS
This first-in-human Phase 1 study evaluated the safety, tolerability, and pharmacokinetics of GAL-101 salt following oral administration to healthy adult and elderly participants.
- Trial name
- GAL-101-C0102 (NCT07780604)
- Testing
- Uncoated GAL-101 Salt 1170 mg, Enteric-Coated Capsules 195 mg, Enteric-Coated Capsules 390 mg
- Where
- South Africa
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Galimedix Therapeutics Inc
Endometriosis
Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of BAY1128688 After Multiple Oral Administrations in Healthy Women
The objective of this trial is to investigate the safety and tolerability of BAY1128688 and to determine the concentration of this substance in blood after repeated administration by the oral route.
- Trial name
- NCT02434640
- Testing
- BAY1128688
- Where
- 3 sites in Germany
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Bayer
Non-alcoholic Fatty Liver Disease
A Clinical Trial of XZP-6019 Tablets in Healthy Subjects
This study will consist of 3 parts: Part A - Single Ascending Dose (SAD) phase, Part B - Food Effect (FE) phase, and Part C - multiple ascending dose (MAD) phase.
- Trial name
- NCT05063968
- Testing
- XZP-6019 tablet
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
Drug-Drug Interaction, Healthy Volunteers
The Effects of Multiple Dose Fluoxetine and Metabolites on CYP1A2, CYP2C19, CYP2D6 and CYP3A4 Activity
Inhibitory drug-drug interactions (DDIs) are a considerable concern as inhibition of drug's clearance can lead to increased plasma concentrations and subsequent adverse events and toxicities.
- Trial name
- FLUOXETINE (NCT01361217)
- Testing
- Fluoxetine, Lovastatin, Omeprazole, caffeine, midazolam, dextromethorphan
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Washington
Alzheimer Disease
Safety, Tolerability and Pharmacokinetics of CMS121, a Drug Candidate for Alzheimer's Disease, in Healthy Subjects
This is a randomized, double-blind study of CMS121 or placebo given as single and multiple escalating doses in normal healthy subjects.
- Trial name
- CMS121 (NCT05318040)
- Testing
- CMS121
- Where
- United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Virogenics, Inc.
Healthy Volunteers
Safety, Tolerability, and Pharmacokinetics of BGB-23339 in Healthy Japanese and Caucasian Subjects
This study is designed to evaluate the influence of ethnic factors on the safety, tolerability, and pharmacokinetics (PK) of BGB-23339 after multiple dosing under fasting condition in healthy Japanese and Caucasian participants.
- Trial name
- NCT05387668
- Testing
- BGB-23339
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- BeiGene
Healthy Volunteer
A Study of RG7667 in Healthy Volunteers
This randomized, double-blind, placebo-controlled study will evaluate the safety and pharmacokinetics of RG7667 in healthy volunteers.
- Trial name
- NCT01496755
- Testing
- RG7667
- Where
- 5 sites in United States
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Healthy
Japanese Single and Multiple Ascending Dose (JSMAD), Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Study of AZD5069
This is a study in Japanese healthy volunteers to determine the safety and tolerability of the compound, AZD5069. It will also assess how the body handles the drug and how it responds to the drug following single and multiple…
- Trial name
- JSMAD (NCT01100047)
- Testing
- AZD5069
- Where
- United Kingdom
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Influenza
A Study of HNC042 in Healthy Chinese Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics
The purpose of this study is to evaluate the safety , tolerability and pharmacokinetics after multiple ascending of HNC042 given to healthy Chinese volunteers, compared to placebo.
- Trial name
- NCT04603989
- Testing
- HNC042 for Injection
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Guangzhou Henovcom Bioscience Co. Ltd.
Infections, Meningococcal
Combined Study - Phase 3b MenB Long Term Persistence in Adolescents
The purpose/aim of this study is to assess 1) the long-term persistence (4 to 7.5 years after the last dose) of bactericidal activity following primary vaccination with rMenB+OMV NZ in adolescents [who previously participated in…
- Trial name
- NCT02446743
- Testing
- rMenB+OMV NZ (Meningococcal (Group B) multi component recombinant adsorbed vaccine)
- Where
- 12 sites in Australia, Canada and 1 more
- Volunteers
- 531 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chemotherapy-induced Diarrhea
A Sequential Single and Multiple Ascending Dose (SAD/MAD) Study of SK10 Powders in Healthy Adult Subjects
The purpose of this study is to assess the safety and tolerability of orally administered SK10 powders in healthy adult subjects at three dose levels, following single and multiple doses.
- Trial name
- NCT06026397
- Testing
- SK10
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Guangzhou Zhiyi Biotechnology Co., Ltd.
Healthy
Single and Multiple Dose Study of Miricorilant (CORT118335) Tablet Formulations in Healthy Participants
This study will assess the safety, tolerability, and pharmacokinetics (PK) of miricorilant (CORT118335) tablet formulations following single and multiple oral administration in healthy participants.
- Trial name
- NCT04672499
- Testing
- Miricorilant 300 mg tablets, Miricorilant 150 mg tablets
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
Healthy Volunteers, Generalized Anxiety Disorder (GAD)
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)
The purpose of this study is to assess the pharmacokinetics, safety, and tolerability following multiple ascending oral doses of ABBV-932 or placebo in healthy adult participants, participants with Generalized Anxiety Disorder…
- Conditions
- Healthy Volunteers, Generalized Anxiety Disorder (GAD), Bipolar Disorder (BPD)
- Trial name
- MAD (NCT06024239)
- Testing
- ABBV-932
- Where
- 3 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy
Pharmacokinetics, Safety and Tolerability of Rising Doses of Buscopan® in Healthy Male Volunteers
Study to investigate pharmacokinetics, safety and tolerability of Buscopan® after single rising dose and after multiple rising doses
- Trial name
- NCT02261077
- Testing
- Hyoscine butylbromide
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Alzheimer's Disease
Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age
The study determined the safety of CNP520 in healthy elderly over 3 months. Data relevant for Pharmacokinetic/Pharmacodynamic modeling were obtained in order to define the target dose in subsequent efficacy studies.
- Trial name
- NCT02576639
- Testing
- CNP520
- Where
- 11 sites in United States, Belgium and 3 more
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.